Randomized, Multicenter Phase II Study of Monoclonal FOLFOX6m + mAb Alone or in Combination With Liver Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease Limited to the Liver With Poor Prognosis

GEMCAD-1802

Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial. The patients will be randomized in a 1: 1 ratio in two arms: Control arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimental arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4. The main objective is to evaluate the radiological objective response rate according to the RECIST version 1.1 criteria at 6 months. Secondary objectives include: Evaluate overall survival, progression-free survival (PFS), safety profile, hepatic PFS, R0 liver surgery rate.

2021-06-29

2024-01-15

2025-01-01

Recruiting

Early phase I

48

Inclusion Criteria: * Patients aged ≥ 18 years. * Patients with colorectal cancer and exclusive liver metastases with poor prognostic criteria,\> 3 lesions and / or size\> 5 cm. Patients with a diagnosis of liver metastases with synchronous presentation or with a disease-free interval may be included. If the primary tumor has not been resected, it must be clinically stable. * Measurable disease following RECIST version 1.1 criteria * Adequate bone marrow function, according to: 1. Hemoglobin ≥ 9.0 g / dl (patients with hemoglobin \<9 g / dl can be transfused before inclusion in the study 2. Platelet count ≥ 100 x 109 / L 3. Absolute Neutrophil Count (ANC) ≥ 1.5x 109 / L * Adequate liver function, according to: 1. Serum bilirubin ≤ 1.5 x the upper limit of normal (ULN) 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN. 3. Alkaline phosphatase ≤ 5 x ULN or ≤10 x ULN in the presence of bone metastases 4. Adequate renal function, with creatinine levels \<1.5 mg / dL. Blood Ureic Nitrogen (BUN)\> 50 ml / min. 5. Albumin\> 3.0 g / dL * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Patients capable of understanding the information and giving their written informed consent to participate in the study * Women of childbearing potential must commit to sexual abstinence or use of barrier contraceptive methods during the study and must have a negative pregnancy test. Exclusion Criteria: * Extension of the disease\> 50% of the liver parenchyma (evaluated by CT performed within the month prior to inclusion) * Previous chemotherapy treatment for metastatic colorectal cancer * Clinically significant cardiovascular diseases: cerebrovascular accident / stroke (≤ 6 months before inclusion in the trial), myocardial infarction (≤ 6 months before inclusion in the trial), unstable angina, uncontrolled hypertension, congestive heart failure of New York Heart Association (NYHA) grade II or higher or severe cardiac arrhythmia. * History of malignancy in the last three years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix treated appropriately. * Altered coagulation (Quick\> 50%) * Patients with active infectious processes * Patients with any of the contraindications specified in the technical data sheet of the study drug or with allergies to some of the drugs used * Pregnant or lactating patients * Portal thrombosis * Severe portal hypertension * Extrahepatic metastases

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Patients will be randomized in a 1: 1 ratio in the 2 arms:\n\nControl Arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimental Arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 48, 'type': 'ESTIMATED'}}

2024-04-10